Sat, Jan 31, 2015, 4:13 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Hemispherx Biopharma, Inc. Message Board

johnnyd_79902 318 posts  |  Last Activity: Jan 30, 2015 11:25 AM Member since: May 13, 1999
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    What Hedge fund doesn't have 35 million?

    by nowwhat654 Jan 29, 2015 7:36 PM
    johnnyd_79902 johnnyd_79902 Jan 30, 2015 11:25 AM Flag

    Too funny. The longer the explanation, the bigger the lie.

    Personally, I really like our Pumper Team - USAMRIID, Swiss DOD, 6 BSL4 labs, the NIH/NIAID, FDA, Arrowhead, Chardan Capital... just for staarters. Quite the Pumper Team, don't you think?

    lol

  • johnnyd_79902 johnnyd_79902 Jan 29, 2015 2:01 PM Flag

    "It is vital that the most promising agents are selected to enter clinical trials. To this extent, WHO is grading proposed treatments on the basis of several criteria, which include supportive in-vitro and animal data, assessment of any existing human data, scalability, and availability.9 The acceleration of clinical trials of selected agents should be encouraged, as should the collection of standardised data in compassionate use settings. Additionally, many of these trials bring an augmented capacity of clinical care, including increased human resources and diagnostic laboratory capabilities that will contribute to improving the standard of care for Ebola-virus-infected patients. Most importantly, we must remember where the greatest burden of disease lies. No matter how effective a treatment might seem in clinical trials, it must be feasible to deliver and be made readily available in all EVD treatment centres in Africa."

    moron

  • johnnyd_79902 johnnyd_79902 Jan 29, 2015 11:29 AM Flag

    And we are so pleased to have USAMRIID and 6 BSL4 labs doing our pumping for us. Animal studies underway!

    moron

  • johnnyd_79902 johnnyd_79902 Jan 29, 2015 10:55 AM Flag

    USAMRIID Reports Genetic Changes in Ebola Virus May Impede Potential Treatments

    Hemispherx's Experimental Biotherapeutics May Escape Mutational Impediments

    "Cellular antiviral pathways of innate immunity are not subject to the mutational pressures of rapidly dividing viruses, which suggests that - even in the face of viral mutation -- biological modifier products activating innate immunity are likely to continue to show sustained biological activity."

  • johnnyd_79902 johnnyd_79902 Jan 29, 2015 10:53 AM Flag

    jsb is a hedge fund idiot.

    "The relatively positive development nonetheless comes as scientists tracking Ebola warned this week that the virus has mutated.

    Anavaj Sakuntabhai, a geneticist at the Institut Pasteur in France, told BBC radio on Thursday that several cases of Ebola have now been seen where the infected person does not appear to have any symptoms.

    "These people may be the ones who could spread the virus better, we do not know yet," Sakuntabhai said. "A virus can change from more deadly into less deadly but more contagious and that is something we are afraid of."

  • johnnyd_79902 johnnyd_79902 Jan 27, 2015 1:05 PM Flag

    "Animal testing is underway"

    Indeed stupid luc.

  • johnnyd_79902 johnnyd_79902 Jan 27, 2015 12:23 PM Flag

    From an earlier paper by U of Texas, publioshed Jan 1, 2015:

    Significance

    As part of the host–pathogen evolutionary arms race, viruses must develop mechanisms to evade host defenses. Viral miRNAs, small regulatory RNAs, are likely key weapons in this struggle. Most previous studies attempted to understand viral miRNA functionality starting with target identification. Here, we use an alternative “functions-first” approach to test the hypothesis that miRNAs from distantly related viruses share common functions. Our work identifies evasion of the antiviral cytokine interferon as a common activity of divergent herpesviral miRNAs. This approach expands our understanding of latent infection and may at least partly explain the resistance of some herpesviral-associated tumors to interferon-mediated therapy. This work demonstrates the utility of functional-based screening for uncovering relevant viral miRNA activities.

    Cytokine interferon???

    Expression of type I and III IFNs can be induced in virtually all cell types upon recognition of viral components, especially nucleic acids, by cytoplasmic and endosomal receptors, whereas type II interferon is induced by cytokines such as IL-12, and its expression is restricted to immune cells such as T cells and NK cells.

    "type II interferon is induced by cytokines such as IL-12, and its expression is restricted to immune cells such as T cells and NK cells."

    USAMRIID is doing us a HUGE service by giving us years of clinical work in a few months. Because what they may find out about ebola, SARS, H7N9, MERS - may apply to a large number of cancers.

  • johnnyd_79902 johnnyd_79902 Jan 27, 2015 12:12 PM Flag

    Stupid luc is nothing but a psychopathic gadfly. A sociopath backing up a psychopath. Quite the pair.

  • johnnyd_79902 johnnyd_79902 Jan 27, 2015 12:09 PM Flag

    Why does stupid luc think he knows more than the US Army???

    "Positive results against Ebola in vitro have been reported to the Company by the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) and other research/academic institutions in the US and abroad. Animal testing is underway and clinical protocol development is also being pursued."

  • johnnyd_79902 johnnyd_79902 Jan 27, 2015 11:11 AM Flag

    luc, is it your goal in life to goad HEB investors?

    ...until the company becomes a success??? It will be a bonus, we won;t have to put up with your psychopathic rantings anymore.

    You'll notice that the discovery is very similar to the discovery of the Ebola virus - e.g. that it blocks the bodies interferon immune response. We are not only in cancer trials, but we are undergoing animal testing by BSL6 labs and USAMRIID. So you can stick your psychopathic bs where the sun don't shine.

    AH

  • Public Release: 26-Jan-2015

    Scientists at The University of Texas at Austin and the University of California at San Francisco have revealed how a type of cancer-causing virus outwits the human body's immune response. The discovery might help explain why some cancer therapies fail to treat certain cancers and might lead to more effective treatments.

    Epstein Barr Virus (EBV), a virus of the herpes family, causes an estimated 200,000 cancers every year, including lymphomas, nasopharyngeal cancers and some stomach cancers. Better anti-viral drugs could help thousands of people suffering from these cancers.

    Many viruses, including EBV, carry small molecules called microRNAs that they use to hijack natural processes in a host's cells during an infection. Viral microRNAs are known to prevent host cell death, promote host cell growth and dampen the host cell's viral defenses. However, scientists don't yet know which viral microRNAs perform which functions.

    Jennifer Cox, a graduate student working with Associate Professor Chris Sullivan at UT Austin, identified microRNAs made by several herpes viruses that block a component of a human's innate immune system called the interferon response. Immune cells within the body release interferon to prevent viral replication, and this often results in slower growth or death of infected host cells. The researchers found that several herpes viruses have independently evolved similar mechanisms to block the host's interferon response.

    "I was actually surprised that all these different viruses had converged on the same mechanism for blocking the body's defenses," said Sullivan. "As a biologist, this is evolutionary gold."

    Interferon is sometimes used in combination with chemotherapy to treat lymphomas. While an effective treatment for some cancers, it does not significantly affect others. This latest research has demonstrated that EBV lymphoma cells are less susceptible to interferon therapy.

  • johnnyd_79902 johnnyd_79902 Jan 26, 2015 12:02 PM Flag

    You guys really need to find smarter trolls. The above post is really pathetic.

  • johnnyd_79902 johnnyd_79902 Jan 26, 2015 11:58 AM Flag

    Carter brought it up 6 months ago at the time saying he thought ampligen/alferon was their best option because of mutation. It appears the army is agreeing. And agreeing in a very public and loud way . lol I think we'll know by April.

  • johnnyd_79902 johnnyd_79902 Jan 26, 2015 11:51 AM Flag

    LOL, "a close reading of the text" - you are hilarious!

    How much does it cost to destroy a macaque ape? Or say, test two drugs in 6 or 8 BSL4 and BSL3 labs??/ Hmmm Mr30ids guy??/

    Looks like you have the tough shift today. lol

  • "Ampligen may be able to overcome this deficiency in host response. Positive results against Ebola in vitro have been reported to the Company by the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) and other research/academic institutions in the US and abroad. Animal testing is underway and clinical protocol development is also being pursued. Clinical trial data will be necessary to establish human efficacy of Ampligen(R) for Ebola viruses."

    Now USAMRIID is spending millions more on Animal testing??/ What's up with that???

    lol LOL!

  • Reply to

    NK-cells

    by pharmainvestor1998 Jan 26, 2015 10:48 AM
    johnnyd_79902 johnnyd_79902 Jan 26, 2015 11:38 AM Flag

    times have changed Mr30idsguy - better get caught up at clinicaltrial dot gov. lol LOL Too dumb to have an opinion on what the NEW protocol is??? Still???

    Updated View Type of info changed
    2005_09_21 Study Nothing (earliest version on record)
    2005_11_01 Study Changes Protocol, Administrative, Misc.
    2005_12_08 Study Changes Internal-use (not shown)
    2006_10_23 Study Changes Protocol, Recruitment, Misc.
    2006_10_24 Study Changes Protocol, Recruitment, Misc.
    2010_04_08 Study Changes Protocol, Recruitment, Location/Contact, Misc.
    2011_09_28 Study Changes Protocol, Recruitment, Location/Contact, Misc.
    2012_10_15 Study Changes Recruitment, Location/Contact, Misc.
    2013_04_16 Study Changes Protocol, Recruitment, Misc.
    2013_07_29 Study Changes Recruitment, Location/Contact, Misc.
    2013_08_15 Study Changes Recruitment, Location/Contact, Misc.
    2014_04_14 Study Changes Recruitment, Misc.
    2014_11_20 Study Changes Protocol, Recruitment, Location/Contact, Misc.

  • Reply to

    NK-cells

    by pharmainvestor1998 Jan 26, 2015 10:48 AM
    johnnyd_79902 johnnyd_79902 Jan 26, 2015 11:35 AM Flag

    "The facts are - Today - that JohnnyD posted a total lie"

    Nope, I don;t believe so --- but it won't be long until we find out for sure, will it? lol LOL

    Still no opinion on what the NEW amp511 protocol is??? Too dumb???

  • Reply to

    NK-cells

    by pharmainvestor1998 Jan 26, 2015 10:48 AM
    johnnyd_79902 johnnyd_79902 Jan 26, 2015 11:30 AM Flag

    Well then Mr30ids guy --- tell us what you think the NEW Protocol will be for the upcoming version of the Amp511???

    Can hardly wait.

  • Reply to

    NK-cells

    by pharmainvestor1998 Jan 26, 2015 10:48 AM
    johnnyd_79902 johnnyd_79902 Jan 26, 2015 11:25 AM Flag

    Mr30ids guy finally reveals his true mental age. Elementary school.

  • Reply to

    NK-cells

    by pharmainvestor1998 Jan 26, 2015 10:48 AM
    johnnyd_79902 johnnyd_79902 Jan 26, 2015 11:24 AM Flag

    Righto, if they only have to infuse 100, and blood test another 200 (CFS and healthy controls) - spread between 5 infusion centers - it will be a snap!

    I'm curious how Argentina will play into this.

HEB
0.2199-0.0001(-0.05%)Jan 30 4:01 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.